Amylyx Pharmaceuticals
PublicAmylyx Pharmaceuticals is now publicly traded
The data on this page reflects Amylyx Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 6, 2022
Last Round
Follow-on Offering
Sep 10, 2025
Total Funding Raised
$960.46M
Company Overview
Amylyx Pharmaceuticals is a biotechnology company focused on the discovery and development of novel therapies for neurodegenerative and endocrine diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
clinical-stage pharmaceutical companyneurodegenerative disease therapiesALS therapy developmentendocrine disease therapiesinvestigational antisense oligonucleotide for ALSinvestigational therapy for Wolfram syndrometherapy for progressive supranuclear palsy (PSP)investigational GLP-1 receptor antagonisttherapy for post-bariatric hypoglycemia (PBH)calpain-2 inhibitor for ALSrare disease drug developmentwithdrawn oral therapy for ALS
Amylyx Pharmaceuticals Comparables
Compare Amylyx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PridCor Therapeutics | 69% | |
| Velvio GmbH | 57% | |
| Guangzhou Magpie Pharmaceuticals Co., Ltd. | 51% | |
Amylyx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Sep 10, 2025 | ||||
| Follow-on Offering | Jan 10, 2025 | ||||
| Follow-on Offering | Oct 11, 2022 | ||||
| IPO | Jan 6, 2022 | ||||
| Series C | Jul 20, 2021 | ||||
Convertible Debt | Feb 1, 2021 |
Key People
Founding team and executive leadership
Amylyx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| Evercore ISI | Follow-on Offering, IPO |
| Bain Capital Life Sciences | Series C |
| 683 Capital Management | Series C |
| Perceptive Advisors | Series C |
| Guggenheim Securities | Follow-on Offering |
| H.C. Wainwright & Co. | Follow-on Offering, IPO |
Amylyx Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersCambridge, Massachusetts
Employee Range161
Year Founded2013
Last FundingSep 10, 2025